MedPath

Effects of Nicotine Replacement and Repeated Cue Exposure on Cigarette Craving

Early Phase 1
Completed
Conditions
Tobacco Use Disorder
Interventions
Behavioral: Cue Extinction Training
Drug: Nicotine Replacement Therapy
Behavioral: Cue Extinction Therapy
Behavioral: Progressive Muscle Relaxation
Registration Number
NCT01329614
Lead Sponsor
Columbia University
Brief Summary

The purpose of this study is to determine whether Cue Extinction Training will reduce relapse rates in cigarette smokers using the patch to quit.

Detailed Description

Nicotine dependence is an important public health problem that contributes to significant morbidity and mortality in our society. Treatment efforts are hampered by high relapse rates, despite the development of somewhat effective treatment modalities, such as Nicotine Replacement Treatment (NRT). NRT, e.g. the nicotine patch, is successful in smoking cessation, compensating for nicotine withdrawal after quitting smoking.

However, relapse rates remain high even in quitters on the patch. It is thought that cravings related to smoking cues contribute to relapse in smokers on the patch who try to quit. Rational treatment approaches for nicotine dependence therefore include strategies to weaken the effect of smoking cues, e.g. cue extinction training (CET). During CET smokers are repeatedly exposed to smoking cues, in the absence of nicotine administration, and smokers report lessening of cue-induced craving (extinction). It is thought that the extinction of smoking cues will result in less control of the smoking cue over smoking behavior and lower relapse rates.

The investigators hypothesize that smoking quit rates on the patch will be higher after CET. To address our hypothesis the investigators first want to develop a proof of concept procedure that demonstrates that repeated cue exposure in the laboratory results in the lessening or 'extinction' of cue-induced craving. In addition, the investigators are interested in the contribution of nicotine withdrawal to cue-induced craving. To this end, the investigators propose to include a control group without nicotine replacement (i.e. placebo patch) that will also undergo the repeated cue exposure procedure.

This study will assess the effect of CET on subsequent craving triggered by smoking cues in cigarette-smoking volunteers. After overnight abstinence, participants will come into the lab, receive a patch (nicotine or placebo) and undergo the CET procedure and perform computer tests and fill out questionnaires.

The main goal of this project is to study the relationship between nicotine replacement, cue-extinction training and subsequent cue-induced craving. Showing the effectiveness of cue-extinction training in the proposed laboratory model will support the application of the cue-extinction procedure to improve relapse rates of nicotine replacement therapies in future clinical trials.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • A DSM-IV Diagnosis of nicotine dependence with physiological dependence. Smoke at least 15 cigarettes daily for two years.
  • Not interested in treatment.
  • Medically healthy on the basis of physical examination and medical history, vital signs, EKG and laboratory tests, with a negative pregnancy test for females.
  • Able to perform study procedures.
  • Males or females between the ages of 21-60 years.
  • Female participants agree to use an effective method of birth control during the course of the study.
Read More
Exclusion Criteria
  • A DSM-IV diagnosis of abuse or dependence on alcohol or drugs other than nicotine.
  • Current Axis I diagnosis or current treatment with psychotropic medications (within last 3 months).
  • Lifetime history of schizophrenia or other psychotic disorders, bipolar disorder, or anxiety disorders.
  • Seeking treatment for nicotine dependence.
  • Participants on parole or probation.
  • History of significant recent violent behavior.
  • Unstable medical condition, Blood Pressure > 150/90, Pregnancy.
  • History of allergic reaction to nicotine patch.
  • Participants with significant cardiac history (i.e. angina pectoris, bypass surgery, or coronary artery disease.)
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Nicotine Replacement Therapy, 7mg doseCue Extinction Therapy-
Nicotine Replacement Therapy, 42mg doseCue Extinction Therapy-
Nicotine Replacement Therapy, 21mg doseCue Extinction Training-
Nicotine Replacement Therapy, 21mg doseProgressive Muscle Relaxation-
Nicotine Replacement Therapy, PlaceboCue Extinction Training-
Nicotine Replacement Therapy, PlaceboCue Extinction Therapy-
Nicotine Replacement Therapy, 42mg doseNicotine Replacement Therapy-
Nicotine Replacement Therapy, 7mg doseCue Extinction Training-
Nicotine Replacement Therapy, 42mg doseProgressive Muscle Relaxation-
Nicotine Replacement Therapy, 7mg doseNicotine Replacement Therapy-
Nicotine Replacement Therapy, 7mg doseProgressive Muscle Relaxation-
Nicotine Replacement Therapy, 21mg doseNicotine Replacement Therapy-
Nicotine Replacement Therapy, PlaceboProgressive Muscle Relaxation-
Nicotine Replacement Therapy, 42mg doseCue Extinction Training-
Nicotine Replacement Therapy, 21mg doseCue Extinction Therapy-
Primary Outcome Measures
NameTimeMethod
Galvanic Skin Response3 days, over the course of 4-5 weeks total.

Measurements of Galvanic Skin Response (GSR) are taken while participant is exposed to the cue. The amount of change in GSR is used to determine CET's impact on cigarette craving.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

New York State Psychiatric Institute - Substance Use Research Center

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath